-- "Nitazoxanide (NTZ) is an Inducer of eIF2a and PKR
phosphorylation," Elazar et al., Tuesday, November 4, 8:00 AM -
12:30 PM PST (Poster #1881)
This poster presentation by Menashe Elazar, Ph.D. of the Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, showed that nitazoxanide increases the intracellular levels of phosphorylated eukaryotic translation initiation factor 2alpha (eIF2alpha), a key mediator of host cell antiviral defenses. Co-treatment with interferon increased nitazoxanide-induced eIF2alpha phosphorylation. . Nitazoxanide was also shown to increase the phosphorylation of protein kinase R (PKR), a key step in the activation of PKR's kinase activity towards eIF2alpha.
"Data presented in each of these communications has provided important information in guiding the ongoing clinical development of nitazoxanide," said Dr. Rossignol.
About Hepatitis C
Hepatitis C is a blood-borne infectious disease that is caused by the
hepatitis C virus (HCV). It is the most common cause of chronic hepatitis
in the U.S. and may eventually lead to cirrhosis, liver cancer and liver
failure. The disease is transmitted by contact with HCV-infected blood. A
large majority of those infected do not show symptoms, but fatigue,
abdominal pain and nausea can be common. The current standard treatment of
care, peginterferon and ribavirin, is effective in about half of all
patients treated. According to the Centers for Disease Control, HCV a
|SOURCE Romark Laboratories|
Copyright©2008 PR Newswire.
All rights reserved